SoftOx Solutions reports Q3 2025 financials, narrows clinical focus

SoftOx Solutions AS has released its third quarter report for 2025, detailing the conclusion of its financial restructuring efforts and a strategic narrowing of its clinical focus to inhalation-therapeutics for chronic lung diseases, specifically cystic fibrosis and non-cystic fibrosis bronchiectasis. The company has secured a flexible financing facility of up to NOK 50 million with Long State Investments Limited, with the first placement of 60 million shares at NOK 0.10 completed in September 2025. This bolsters liquidity for planned clinical trials and ongoing operations.

SoftOx reported a pre-tax loss of NOK 5.5 million for Q3 2025 (compared to a loss of NOK 17.9 million in Q3 2024), and a loss of NOK 6.9 million for the first three quarters of 2025 (versus NOK 46.9 million in the prior year). Total operating revenue reached NOK 11.97 million for the first three quarters of 2025, with total operating expenses at NOK 19.5 million. Cash and cash equivalents stood at NOK 20.06 million at the end of September 2025.

The Clinical Trial Application (CTA) for the proof-of-concept trial was submitted in September 2025, with study initiation expected in Q1 2026. Simultaneously, SoftOx Defense Solutions AS continues its work on inhaled medical countermeasures under a collaborative agreement with the European Defence Fund, with its CTA for a Phase 1 clinical trial submitted in mid-October 2025.